Search our Database of Scientific Publications and Authors

I’m looking for a

    8778 results match your criteria Psoriatic Arthritis

    1 OF 176

    An unexpected cause of sacroiliitis in a patient with gout and chronic psoriasis with inflammatory arthritis: a case report.
    BMC Musculoskelet Disord 2018 Apr 20;19(1):126. Epub 2018 Apr 20.
    Rheumatology Department, Cork University Hospital, Cork, Ireland.
    Background: Inflammatory back pain is a condition characterized by inflammation of the sacroiliac joints and lower spine. It is frequently seen in patients with spondyloarthropathies like ankylosing spondylitis, psoriatic arthritis, enteropathic arthritis and reactive arthritis. Inflammatory back pain can be caused by many other conditions like infection and crystal deposition such as gout. Read More

    Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate to severe plaque psoriasis.
    J Dermatolog Treat 2018 Apr 20:1-20. Epub 2018 Apr 20.
    a Pharmacy Department , Hospital General Universitario Gregorio Marañón , Madrid , Spain.
    Purpose: The aim of this study was to identify clinical factors associated with dose reduction and dose escalation in the treatment with ustekinumab in patients with moderate to severe plaque psoriasis.

    Materials And Methods: An observational, longitudinal and retrospective study was conducted using patients with moderate to severe plaque psoriasis. We reviewed clinical histories and variables were recorded on a database (patients' characteristics, pharmacotherapeutics, effectiveness and safety). Read More

    A Case of Psoriasis Complicated by Breast Cancer after Systemic Treatments Including Biologics.
    Acta Med Okayama 2018 Apr;72(2):185-187
    Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558,
    Psoriasis is a common chronic inflammatory skin disorder that is characterized by scaly, erythematous, sharply demarcated plaques. The treatment for psoriasis has dramatically changed over the last 10 years with the introduction of biologics. However, the risk of cancer induced by biologics for psoriasis has not been fully analyzed, since these agents have such a short history of use. Read More

    Imaging to Differentiate the Various Forms of Seronegative Arthritis.
    Semin Musculoskelet Radiol 2018 Apr 19;22(2):189-196. Epub 2018 Apr 19.
    Department of Radiology, National Institute of Geriatrics, Rheumatology and Rehabilitation and Imaging Diagnostic Department, Warsaw Medical University, Warsaw, Poland.
    Spondyloarthritis (SpA) is a group of diseases characterized by back pain, spinal inflammation, human leukocyte antigen-B27 positivity, and peripheral findings such as dactylitis, enthesitis, and uveitis. It includes ankylosing spondylitis, psoriatic arthritis, reactive arthritis, arthritis associated with inflammatory bowel disease, and undifferentiated SpA. The role of imaging in the diagnosis, management, and follow-up of patients with SpA has become dramatically more important with the introduction of new therapies such as tumor necrosis factor-α inhibitors. Read More

    Psoriatic Arthritis and Nail Psoriasis in a Patient with Concomitant Atopic Dermatitis.
    Case Rep Dermatol Med 2018 18;2018:4125856. Epub 2018 Feb 18.
    Department of Rheumatology, Hutt Hospital, Lower Hutt, New Zealand.
    Coincidence of psoriasis and atopic dermatitis (AD) is considered to be very rare, as a result of the different underlying immunopathology. This case report describes a patient with long history of atopy and AD who developed psoriatic nail changes and psoriatic arthritis (PsA). The patient's skin, however, revealed only eczematous lesions without manifestation of psoriasis. Read More

    Distinct T-Helper 17 Differentiation Capacity of Peripheral Naive T Cells in Rheumatoid and Psoriatic Arthritis.
    Front Immunol 2018 4;9:606. Epub 2018 Apr 4.
    Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary.
    Background: The T-helper 17 (Th17) cells have a prominent role in inflammation as well as in bone and join destruction in both rheumatoid and psoriatic arthritis (RA and PsA). Here, we studied Th17 cell differentiation in RA and PsA.

    Methods: Blood samples from healthy donors, RA and PsA patients were collected. Read More

    Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies.
    Mediators Inflamm 2018 12;2018:2403935. Epub 2018 Feb 12.
    Department of Medicine, Division of Allergy, Immunology and Rheumatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
    Spondyloarthropathy (SpA) is a unique type of joint inflammation characterized by coexisting erosive bone damage and pathological new bone formation. Previous genetic association studies have demonstrated that several cytokine pathways play a critical role in the pathogenesis of ankylosing spondylitis (AS), psoriatic arthritis (PsA), and other types of SpA. In addition to several well-known proinflammatory cytokines, recent studies suggest that IL-17 plays a pivotal role in the pathogenesis of SpA. Read More

    Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors.
    Clin Rheumatol 2018 Apr 18. Epub 2018 Apr 18.
    RPA Institute of Rheumatology and Orthopaedics, Camperdown, NSW, Australia.
    The aim was to describe the real-world treatment persistence of subcutaneous TNF inhibitors (TNFi) for patients with inflammatory rheumatic disease newly initiating treatment with biologic disease-modifying antirheumatic drugs (bDMARD). This was a retrospective cohort study that extracted data for new users of TNFi between 1 August 2010 and 31 August 2016 from the Australian Optimising Patient outcome in Australian RheumatoLogy (OPAL) registry. Patients were 1:1 propensity-score matched with golimumab based on their age, sex, year of index, C-reactive protein level, baseline treatment combination and disease. Read More

    Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNFα Monoclonal Antibody.
    AAPS J 2018 Apr 17;20(3):63. Epub 2018 Apr 17.
    Global Clinical Pharmacology, Janssen R&D, LLC, Spring House, Pennsylvania, 19477, USA.
    A prominent example of human therapeutic protein-drug interaction (TP-DI) is between methotrexate (MTX) and anti-TNFα mAbs. One plausible mechanism for this TP-DI is through the pharmacodynamic effect of MTX on immunogenicity. However, there is no definitive evidence to substantiate this mechanism, and other competing hypotheses, such as MTX suppressing FcγRI expression thereby affecting mAb PK, have also been proposed. Read More

    A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis.
    Case Rep Gastrointest Med 2018 15;2018:9679287. Epub 2018 Feb 15.
    Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
    Secukinumab is an interleukin-17 inhibitor used for the treatment of ankylosing spondylitis (AS), psoriasis, and psoriatic arthritis. The risk of exacerbating underlying inflammatory bowel disease (IBD) in patients being treated with secukinumab for other conditions is controversial. We document a patient with AS and previously undiagnosed IBD, found to be in a severe ulcerative colitis flare shortly after receiving the loading dose of secukinumab. Read More

    Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study.
    Arthritis Res Ther 2018 Apr 17;20(1):73. Epub 2018 Apr 17.
    Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland.
    Background: The efficacy of corticosteroids in patients with psoriatic arthritis (PsA) and inflammatory back pain has not been studied to date. In this controlled trial, we aimed to investigate the comparative performance of corticosteroids in patients with active axial-PsA (AxPsA) versus those with active ankylosing spondylitis (AS).

    Methods: Patients with AxPsA and AS (naïve to biologic therapies), who not only had clinically active disease, but also had bone marrow oedema on magnetic resonance imaging of the sacroiliac joints, were recruited. Read More

    MIF functional polymorphisms (-794 CATT and -173 G>C) are associated with MIF serum levels, severity and progression in male multiple sclerosis from western Mexican population.
    J Neuroimmunol 2018 Apr 10. Epub 2018 Apr 10.
    Instituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico. Electronic address:
    Macrophage migration inhibitory factor (MIF) is a cytokine associated with tissue damage in multiple autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis and psoriatic arthritis. The role of MIF in multiple sclerosis (MS) and the contribution of its polymorphisms are unknown in our population. Therefore, we decided to investigate the genetic association of -794 CATT (rs5844572) and -173 G>C (rs755622) MIF polymorphisms with MS, clinical variables and MIF serum levels in the population of western Mexico. Read More

    Temporomandibular Joint Reconstruction in Patients With Autoimmune/Connective Tissue Disease.
    J Oral Maxillofac Surg 2018 Mar 22. Epub 2018 Mar 22.
    Resident, Department of Oral and Maxillofacial Surgery, Boston University School of Dental Medicine and Boston Medical Center, Boston, MA.
    Purpose: To evaluate clinical outcomes in patients with autoimmune or connective tissue (CT) disease undergoing temporomandibular joint (TMJ) reconstruction.

    Materials And Methods: Patients were divided into 2 groups based on type of TMJ reconstruction. Patients in group 1 (n = 9) underwent autogenous reconstruction and had a diagnosis of rheumatoid arthritis (5), lupus arthritis (1), and psoriatic arthritis (3). Read More

    Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis.
    RMD Open 2018 9;4(1):e000667. Epub 2018 Apr 9.
    Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli, Catholic University of the Sacred Heart, Rome, Italy.
    Objective: Paradoxical arthritis under tumour necrosis factor inhibitor (TNF-i) for inflammatory bowel disease (IBD) has been described. This study aims to evaluate the histological features of paired synovial tissue (ST) and colonic mucosa (CM) tissue in patients with IBD developing paradoxical arthritis under TNF-i.

    Methods: Patients with IBD without history of coexisting joint involvement who developed arthritis under TNF-i were enrolled. Read More

    Power Doppler Ultrasound Evaluation of Peripheral Joint, Entheses, Tendon, and Bursa Abnormalities in Psoriatic Patients: A Clinical Study.
    J Rheumatol 2018 Apr 15. Epub 2018 Apr 15.
    From the Department of Ultrasound, West China Hospital of Sichuan University, Chengdu, Sichuan, China. Supported by grants from the National Natural Science Foundation of China (81671696 and 51703141), the Sichuan Science and Technology Plan (2015 SZ0125), and the Chengdu Science and Technology Plan (2014-HM01-00176-SF). Y. Tang, MM, Department of Ultrasound, West China Hospital of Sichuan University; Y. Yang, BS, Department of Ultrasound, West China Hospital of Sichuan University; X. Xiang, BS, Department of Ultrasound, West China Hospital of Sichuan University; L. Wang, BS, Department of Ultrasound, West China Hospital of Sichuan University; L. Zhang, MM, Department of Ultrasound, West China Hospital of Sichuan University; L. Qiu, MD, Department of Ultrasound, West China Hospital of Sichuan University. Address correspondence to Dr. L. Qiu, Department of Ultrasound, West China Hospital of Sichuan University, No. 37 Guo Xue Xiang, Chengdu 610041, Sichuan, China. E-mail: Accepted for publication November 29, 2017.
    Objective: To evaluate the prevalence rates of peripheral joint, enthesis, tendon, and bursa abnormalities by power Doppler (PD) ultrasonic examination in patients with psoriatic arthritis (PsA), psoriatic patients without clinical signs of arthritis (non-PsA psoriasis group), and healthy individuals, to detect subclinical PsA.

    Methods: A total of 253 healthy volunteers, 242 non-PsA psoriatic patients, and 86 patients with PsA were assessed by 2-dimensional and power Doppler (PD) ultrasound. Peripheral joint, enthesis, tendon, and bursa abnormalities were observed, characterizing abnormal PD. Read More

    Cardiovascular risk factors predicting cardiac events are different in patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis.
    Semin Arthritis Rheum 2018 Mar 17. Epub 2018 Mar 17.
    Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff University, Cardiff, United Kingdom.
    Objectives: Increased cardiovascular risk in rheumatoid arthritis (RA) is well established. Examining traditional cardiovascular risk factors alone underestimates cardiovascular risk in RA. Systematic inflammation, measured by erythrocyte sedimentation rate or C-reactive protein is also a major risk factor. Read More

    Relevance and feasibility of a systematic screening of multimorbidities in patients with chronic inflammatory rheumatic diseases.
    Joint Bone Spine 2018 Apr 11. Epub 2018 Apr 11.
    Department of Rheumatology, CHU Montpellier, 34000 Montpellier, France; Montpellier University, 34000 Montpellier, France; National Institute for Health and Medical Research (INSERM), U1046, 34000 Montpellier, France.
    Objectives: EULAR recently proposed to screen multimorbidities in chronic inflammatory rheumatic diseases. The aims of the study were to (i) define the most common multimorbidities in chronic inflammatory rheumatic diseases, (ii) compare the screening approach performed in the clinic with the recent EULAR recommendations, (iii) validate the points to consider for the systematic standardized multimorbidity screening proposed by EULAR and (iv) assess feasibility of such a screening in a daily clinic.

    Methods: Data were collected prospectively during a 1-day multimorbidity clinic. Read More

    Sympathetic Nerve Hyperactivity in the Spleen: Causal for Nonpathogenic-Driven Chronic Immune-Mediated Inflammatory Diseases (IMIDs)?
    Int J Mol Sci 2018 Apr 13;19(4). Epub 2018 Apr 13.
    College of Arts and Sciences, Kent State University, Kent, OH 44304, USA.
    Immune-Mediated Inflammatory Diseases (IMIDs) is a descriptive term coined for an eclectic group of diseases or conditions that share common inflammatory pathways, and for which there is no definitive etiology. IMIDs affect the elderly most severely, with many older individuals having two or more IMIDs. These diseases include, but are not limited to, type-1 diabetes, obesity, hypertension, chronic pulmonary disease, coronary heart disease, inflammatory bowel disease, and autoimmunity, such as rheumatoid arthritis (RA), Sjőgren's syndrome, systemic lupus erythematosus, psoriasis, psoriatic arthritis, and multiple sclerosis. Read More

    [Physical therapy of psoriasis. The modern methodological approaches].
    Vopr Kurortol Fizioter Lech Fiz Kult 2018 Apr 9;95(1):53-58. Epub 2018 Apr 9.
    Russian Medical Academy of Continuous Professional Education.
    This article describes the modern approaches to the application of physical factors for the treatment of various forms of psoriasis taking into consideration the severity of clinical manifestations and the phase of the disease, the extent of disturbances of the functional state of different organs. The principles of prescription of physiotherapeutictreatmnt are formulated taking account of the stages and forms of the disease. Special attention is paid to the high therapeutic effectiveness of ultraviolet irradiation of the skin including narrow-band UVВ (311 nm) as well as to photodynamic therapy (PUVA), intravenous laser irradiation of blood, and ozone therapy. Read More

    The Georgian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).
    Rheumatol Int 2018 Apr 7;38(Suppl 1):203-209. Epub 2018 Apr 7.
    Clinica Pediatrica e Reumatologia, Paediatric Rheumatology International Trials Organisation (PRINTO), Istituto Giannina Gaslini, Via Gaslini 5, 16147, Genoa, Italy.
    The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Georgian language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Read More

    The Slovak version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).
    Rheumatol Int 2018 Apr 7;38(Suppl 1):355-361. Epub 2018 Apr 7.
    Clinica Pediatrica e Reumatologia, Paediatric Rheumatology International Trials Organisation (PRINTO), Istituto Giannina Gaslini, Via Gaslini 5, 16147, Genoa, Italy.
    The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Slovak language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Read More

    The Thai version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).
    Rheumatol Int 2018 Apr 7;38(Suppl 1):387-393. Epub 2018 Apr 7.
    Clinica Pediatrica e Reumatologia, Paediatric Rheumatology International Trials Organisation (PRINTO), Istituto Giannina Gaslini, Via Gaslini 5, 16147, Genoa, Italy.
    The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Thai language. The reading comprehension of the questionnaire was tested in ten JIA parents and patients. Read More

    The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).
    Rheumatol Int 2018 Apr 7;38(Suppl 1):195-201. Epub 2018 Apr 7.
    Clinica Pediatrica e Reumatologia, Paediatric Rheumatology International Trials Organisation (PRINTO), Istituto Giannina Gaslini, Via Gaslini 5, 16147, Genoa, Italy.
    The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the French language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Read More

    Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology.
    Rheumatol Int 2018 Apr 7;38(Suppl 1):5-17. Epub 2018 Apr 7.
    Clinica Pediatrica e Reumatologia, Paediatric Rheumatology International Trials Organisation (PRINTO), Istituto Giannina Gaslini, Via Gaslini 5, 16147, Genoa, Italy.
    The aim of this project was to cross-culturally adapt and validate the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) questionnaire in 54 languages across 52 different countries that are members of the Paediatric Rheumatology International Trials Organisation (PRINTO). This effort was part of a wider project named Epidemiology and Outcome of Children with Arthritis (EPOCA) to obtain information on the frequency of juvenile idiopathic arthritis (JIA) categories in different geographic areas, the therapeutic approaches adopted, and the disease status of children with JIA currently followed worldwide. A total of 13,843 subjects were enrolled from the 49 countries that took part both in the cross-cultural adaptation phase and in the related validation and data collection: Algeria, Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czech Republic, Denmark, Ecuador, Egypt, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, India, Islamic Republic of Iran, Israel, Italy, Latvia, Libya, Lithuania, Mexico, Netherlands, Norway, Oman, Paraguay, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Serbia, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Thailand, Turkey, Ukraine, United Kingdom and United States of America. Read More

    Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial.
    Rheumatology (Oxford) 2018 Apr 4. Epub 2018 Apr 4.
    West Tennessee Research Institute, Jackson, TN, USA.
    Objectives: The PALACE 4 trial evaluated apremilast monotherapy in patients with active PsA who were DMARD-naive.

    Methods: Eligible patients were randomized (1:1:1) to placebo, apremilast 20 mg twice a day or apremilast 30 mg twice a day. At week 16 or 24, placebo patients were rerandomized to apremilast. Read More

    The impact of psoriasis on professional life: PsoPRO, a French national survey.
    J Eur Acad Dermatol Venereol 2018 Apr 6. Epub 2018 Apr 6.
    Medicine and Occupational Health, Centre Hospitalier Universitaire (CHU) Angers, Angers, France.
    Background: The physical, social and mental burden of psoriasis is well known but its occupational impact has been less investigated.

    Objective: To assess the impact of psoriasis on the working life of patients compared with the general population.

    Methods: A national survey that compared people with and without psoriasis using online questionnaires. Read More

    Is treat-to-target in lupus nephritis realistic in clinical practice?
    Curr Rheumatol Rev 2018 Apr 5. Epub 2018 Apr 5.
    Department of Medicine, Tuen Mun Hospital, Hong Kong, SAR . China.
    The treat-to-target (T2T) principle has been advocated in a number of inflammatory and non-inflammatory medical illnesses. Tight control of disease activity has been shown to improve the outcome of rheumatoid arthritis and psoriatic arthritis as compared to the conventional approach. However, whether T2T can be applied to patients with lupus nephritis is still under hot discussion. Read More

    The role of genetics and epigenetics in rheumatic diseases: are they really a target to be aimed at?
    Rheumatol Int 2018 Apr 5. Epub 2018 Apr 5.
    Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, N15W7, Kita-Ku, Sapporo, 060-8638, Japan.
    To date, numerous genetic and epigenetic studies have been performed and provided a crucial step forward in our understanding of the pathogenesis of rheumatic diseases. However, most of the recent advances in the treatment of rheumatic diseases including biological therapies are not based on or even discrepant from these genetic and epigenetic findings. For example, tumor necrosis factor inhibitors are quite successful in the treatment of rheumatoid arthritis (RA), Behçet's disease (BD), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) but not in that of systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's syndrome (SS) and antineutrophil cytoplasmic antibody-associated vasculitis (AAV), conversely, RA shares genetic backgrounds more with SLE, SSc, SS and AAV than BD, AS and PsA. Read More

    Association between Vitamin D deficiency and psoriasis: An exploratory study.
    Int J Health Sci (Qassim) 2018 Jan-Feb;12(1):33-9
    Department of Dermatology, College of Medicine, Qassim University, Saudi Arabia.
    Introduction: Deficiency of Vitamin D is a widespread problem. Vitamin D could have important immune modulatory effects in psoriasis.

    Objective: Aimed to review and endeavored to establish the relationship, if any, between deficiency of Vitamin D and psoriasis. Read More

    Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis.
    Rheumatology (Oxford) 2018 Apr 2. Epub 2018 Apr 2.
    The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
    Objectives: We sought to investigate the selection of specific biological DMARDs (bDMARDs) based on characteristic lymphocyte phenotypes for treating PsA.

    Methods: Of 64 patients with PsA resistant to MTX, 26 underwent bDMARDs therapy selected according to phenotypic differences in peripheral helper T cells on 8-colour flow cytometry. The efficacies of this strategic treatment and the standard treatment administered to the other 38 patients were evaluated at 6 months. Read More

    Quality of Care in Rheumatoid Disease from the Clinician Perspective: A Modified Delphi Panel Approach.
    Rheumatol Ther 2018 Apr 3. Epub 2018 Apr 3.
    Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA.
    Introduction: To establish clinical consensus on important and relevant quality-of-care (QoC) attributes in rheumatic disease (RD) treatment that may improve treatment outcomes and guide best practices.

    Methods: Twenty-three QoC attributes were identified in a literature review. Fifteen European-based clinicians were selected based on their contributions to RD guidelines, publications, and patient care. Read More

    Role of Methotrexate in the Management of Psoriatic Arthritis.
    Drugs 2018 Apr 3. Epub 2018 Apr 3.
    Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada.
    Methotrexate is known to be safe and efficacious in the management of rheumatoid arthritis and psoriasis and thus has been used for the management of psoriatic arthritis despite a lack of evidence to support efficacy in psoriatic arthritis from randomized controlled trials. Although the largest randomized trial to date did not support its use as a disease-modifying therapy, observational studies have supported its role, and current treatment recommendations approve of its use as a first-line agent for the management of psoriatic arthritis with predominant peripheral arthritis. The first treat-to-target study in psoriatic arthritis, comparing tight control with standard care, has shown the efficacy of methotrexate as monotherapy in the first 12 weeks. Read More

    Common and Not-So-Common Comorbidities of Psoriasis.
    Semin Cutan Med Surg 2018 Feb;37(2S):S48-S51
    Director of Dermatology Research Department of Dermatology Kaiser Permanente Los Angeles Medical Center Los Angeles, California.
    Plaque psoriasis is increasingly recognized as a multisystemic disease whose most common comorbidities include psoriatic arthritis, cardiovascular disease, metabolic syndrome, overweight/obesity, inflammatory bowel disease, and depression. The presence of such comorbidities affects the therapeutic choices for clinicians. Patients often visit dermatologists more frequently than they do other clinicians, so it is incumbent upon dermatologists to recognize and address early signs of psoriatic comorbidities to prevent further deterioration and improve their patients' quality of life. Read More

    Psoriasis.
    Ann Intern Med 2018 Apr;168(7):ITC49-ITC64
    Icahn School of Medicine at Mount Sinai, New York, New York (M.L.).
    Psoriasis, an inherited disorder of the immune system, presents most commonly in the skin and joints but is also associated with cardiovascular, metabolic, and neuropsychiatric effects. Treatments include topical therapy for mild disease; phototherapy and oral therapy, such as retinoids and immunomodulating agents; and targeted biologic therapies that have revolutionized treatment of psoriasis and psoriatic arthritis. Primary care physicians should be aware of the systemic associations of psoriasis and the treatments available for this disorder. Read More

    Clinical features of children with enthesitis-related juvenile idiopathic arthritis / juvenile spondyloarthritis followed in a French tertiary care pediatric rheumatology centre.
    Pediatr Rheumatol Online J 2018 Apr 2;16(1):21. Epub 2018 Apr 2.
    Pediatric Immunology, Hematology, and Rheumatology Unit, Centre de Référence pour les Rhumatismes Inflammatoires et les Maladies Auto-Immunes Systémique Rare de l'Enfant (RAISE) ; Necker-Enfants Malades Hospital, Assistance Publique Hôpitaux de Paris, 149, rue de Sèvres, 75743 Cedex15, Paris, France.
    Background: Childhood-onset spondyloarthropathies usually start with enthesitis and peripheral arthritis. However, axial disease may develop afterward. Patients are most often classified, following revised (Edmonton 2011) ILAR criteria, as enthesitis-related arthritis, psoriatic arthritis, or unclassified juvenile idiopathic arthritis, particularly in cases of psoriasis in the patient or a first-degree relative. Read More

    Burden of Psoriatic Arthritis in different definitions of disease activity: comparing Minimal Disease Activity and Disease Activity index for Psoriatic Arthritis.
    Arthritis Care Res (Hoboken) 2018 Apr 2. Epub 2018 Apr 2.
    Erasmus University Hospital, Department of Rheumatology, Wytemaweg 80, 3015 CN, Rotterdam, the Netherlands.
    Objective: Treat-to-target strategies have improved outcomes in rheumatic diseases. In psoriatic arthritis (PsA), the proposed targets are the multidimensional target Minimal Disease Activity (MDA) and the articular target Disease Activity index for PsA (DAPSA). We aimed to compare burden of PsA in patients with low disease activity according to the two definitions MDA and DAPSA-Low Disease Activity (DAPSA-LDA), one year after diagnosis. Read More

    Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
    Arthritis Care Res (Hoboken) 2018 Apr 2. Epub 2018 Apr 2.
    Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland.
    Objective: The primary objective of this study was to compare the risk of major cardiovascular events (MACE) in a large observational cohort of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) patients METHODS: We conducted a mixed retrospective and prospective cohort study using data from patients with RA, PsA and axSpA included in the Swiss Clinical Quality Management registry. The primary outcome of interest was a composite of myocardial infarction, transient or permanent cerebrovascular event, or CV associated death.

    Results: 5,315 patients were eligible for the analysis of incidence with a total follow-up time of 37,495 patient years for RA, 19,837 for AxSpA, and 9,171 for PsA. Read More

    Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
    J Rheumatol 2018 Apr 1. Epub 2018 Apr 1.
    From the Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Heraklion; Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina; Rheumatology Department, Sismanoglio Hospital; Department of Nutrition and Dietetics, Harokopio University of Athens; Department of Rheumatology, Veterans Administration Hospital; Joint Academic Rheumatology Program, Faculty of Medicine, National and Kapodestrian University of Athens; Fourth Internal Medicine Department, Attikon University Hospital of Athens, Athens; Rheumatology Clinic, General Hospital of Kavala, Kavala; First Department of Internal Medicine, Rheumatology Section, AHEPA Hospital of the Aristotle University Medical School; Rheumatology Department, 424 General Army Hospital, Thessaloniki, Greece; Department of Rheumatology, Skȧne University Hospital, Lund, Sweden. This work was supported in part by the Hellenic Rheumatology Society through unrestricted grants from Schering-Plough, AbbVie, Pfizer, Bristol Myers Squibb, and Roche. These companies had no role in study design, collection, analysis and interpretation of the data, in the writing of the manuscript, or in the decision to submit the manuscript for publication. I.D. Flouri, MD, Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete; T.E. Markatseli, MD, PhD, Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina; K.A. Boki, MD, PhD, Rheumatology Department, Sismanoglio Hospital; I. Papadopoulos, MD, PhD, Rheumatology Clinic, General Hospital of Kavala; F.N. Skopouli, MD, PhD, Department of Nutrition and Dietetics, Harokopio University of Athens; P.V. Voulgari, MD, PhD, Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina; L. Settas, MD, PhD, First Department of Internal Medicine, Rheumatology Section, AHEPA Hospital of the Aristotle University Medical School; D. Zisopoulos, MD, First Department of Internal Medicine, Rheumatology Section, AHEPA Hospital of the Aristotle University Medical School, and Rheumatology Department, 424 General Army Hospital; A. Iliopoulos, MD, PhD, Department of Rheumatology, Veterans Administration Hospital; P. Geborek, MD, PhD, Department of Rheumatology, Skȧne University Hospital; A.A. Drosos, MD, PhD, Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina; D.T. Boumpas, MD, PhD, Joint Academic Rheumatology Program, Faculty of Medicine, National and Kapodestrian University of Athens, and Fourth Internal Medicine Department, Attikon University Hospital of Athens; P. Sidiropoulos, MD, PhD, Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete. Address correspondence to Dr. P. Sidiropoulos, Rheumatology, Clinical Immunology and Allergy, University of Crete Medical School, Voutes, 71110, Heraklion, Greece. E-mail: Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication November 27, 2017.
    Objective: To evaluate the 10-year drug survival of the first tumor necrosis factor inhibitor (TNFi) administered to patients with spondyloarthritis (SpA) overall and comparatively between SpA subsets, and to identify predictors of drug retention.

    Methods: Patients with SpA in the Hellenic Registry of Biologic Therapies, a prospective multicenter observational cohort, starting their first TNFi between 2004-2014 were analyzed. Kaplan-Meier curves and Cox regression models were used. Read More

    Simultaneous Response in Several Domains in Patients with Psoriatic Disease Treated with Etanercept as Monotherapy or in Combination with Conventional Synthetic Disease-modifying Antirheumatic Drugs.
    J Rheumatol 2018 Apr 1. Epub 2018 Apr 1.
    From the CIRI/Rheumatology and Fraunhofer Institute IME, Translational Medicine and Pharmacology, Goethe University, Frankfurt; Rheuma Praxis Hofheim, Hofheim am Taunus; Department of Dermatology, Ludwig-Maximilians-University of Munich, Munich; Pfizer Pharma GmbH, Berlin, Germany; Universitätsklinikum Heidelberg, Heidelberg, and ACURA Center for Rheumatic Diseases, Baden-Baden, Germany. This study was funded by Pfizer. Medical writing support was provided by Samantha Forster and Jennica Lewis of Engage Scientific Solutions and was funded by Pfizer. Dr. Behrens has received honoraria, speaker's fees, compensation for consultancies, board memberships, or study documentation from Pfizer, Abbvie, Chugai, Roche, UCB, Lilly, Celgene, MSD, Novartis, and Janssen-Cilag. Dr. Lorenz has received honoraria for talks and consultation from Pfizer. J. Jobst, Dr. Lippe, and Dr. Löschmann are employees of Pfizer. F. Behrens, MD, CIRI/Rheumatology and Fraunhofer Institute IME, Translational Medicine and Pharmacology, Goethe University; L. Meier, MD, Rheuma Praxis Hofheim; J.C. Prinz, MD, Professor and Vice Chair, Department of Dermatology, Ludwig-Maximilian-University of Munich; J. Jobst, PhD, Pfizer Pharma GmbH; R. Lippe, MD, Pfizer Pharma GmbH; P.A. Löschmann, MD, Pfizer Pharma GmbH; H.M. Lorenz, MD, Professor of Medicine, Universitätsklinikum Heidelberg and ACURA Center for Rheumatic Diseases. Address correspondence to Dr. F. Behrens, CIRI/Rheumatology and Fraunhofer Institute IME, Translational Medicine and Pharmacology, Goethe University, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany. E-mail: Accepted for publication December 27, 2017.
    Objective: To evaluate patients with psoriatic arthritis (PsA) receiving etanercept (ETN) monotherapy or ETN plus conventional synthetic disease-modifying antirheumatic drugs (csDMARD) to determine the proportion achieving a clinically meaningful response in arthritis, psoriasis, and quality of life simultaneously.

    Methods: A prospective, multicenter, 52-week observational study in patients with active PsA evaluated treatment with ETN in clinical practice (ClinicalTrials.gov: NCT00293722). Read More

    Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.
    Rheumatol Ther 2018 Mar 31. Epub 2018 Mar 31.
    Novartis Pharma AG, Basel, Switzerland.
    Introduction: Secukinumab and adalimumab are approved for adults with active psoriatic arthritis (PsA). In the absence of direct randomized controlled trial (RCT) data, matching-adjusted indirect comparison can estimate the comparative effectiveness in anti-tumor necrosis factor (TNF)-naïve populations.

    Methods: Individual patient data from the FUTURE 2 RCT (secukinumab vs. Read More

    Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions.
    Int J Cancer 2018 Mar 30. Epub 2018 Mar 30.
    Department of Public Health Sciences, The University of Chicago, Chicago, IL.
    Based on limited evidence, the U.S. Food and Drug Administration (FDA) issued a black box warning for the use of tumor necrosis factor-alpha inhibitors (TNFIs) and risk of non-Hodgkin lymphoma (NHL). Read More

    Clinical remission in rheumatoid arthritis and psoriatic arthritis.
    Clin Exp Rheumatol 2018 Mar 16. Epub 2018 Mar 16.
    Early Arthritis Clinic, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Italy.
    It is currently recognised that remission can be an achievable target for several rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients by a treat-to-target approach. For RA different remission criteria have been proposed, depending on the disease activity scores used, on the importance given to the inclusion of patients' perspective into the definition of remission, and on their applicability in clinical practice, that generate highly different remission rates. Conversely, for PsA, remission is still insufficiently defined and represents a partially unmet need. Read More

    Sacroiliitis in Children With Familial Mediterranean Fever.
    J Clin Rheumatol 2018 Mar 29. Epub 2018 Mar 29.
    Background/objective: Familial Mediterranean fever (FMF) is an autosomal recessive disease, characterized by recurrent, self-limited attacks of fever with serositis. Various diseases were reported to be associated with FMF. The aim of this study was to investigate the frequency and characteristics of sacroiliitis in children with FMF. Read More

    The Influence of Connective Tissue Disease in Breast Reconstruction: A National Database Analysis.
    Ann Plast Surg 2018 Apr;80(4 Suppl 4):S182-S188
    From the Division of Plastic and Reconstructive Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
    Background: Patients with connective tissue diseases (CTD), or collagen vascular diseases, are at risk of potentially higher morbidity after surgical procedures. We aimed to investigate the complication profile in CTD versus non-CTD patients who underwent breast reconstruction on a national scale.

    Methods: A retrospective analysis of the Healthcare Cost and Utilization Project NIS Database between 2010 and 2014 was conducted for patients 18 years or older admitted for immediate autologous or implant breast reconstruction. Read More

    [Biological treatment of psoriatic arthritis].
    Vnitr Lek 2018 ;64(2):127-135
    Psoriatic arthritis (PsA) is a heterogeneous disease affecting, besides synovial joints, also the entheses, the soft tissues of the whole finger (dactylitis) and the axial skeleton. Currently the classification criteria CASPAR are used to diagnose PsA. In a large number of patients the disease leads to irreversible joint damage (X-ray, respectively clinical) which significantly reduces life quality and limits the patient in his/her everyday activities and also considerably limits their work capacity. Read More

    1 OF 176